Stockreport

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting [Yahoo! Finance]

MiNK Therapeutics, Inc.  (INKT) 
PDF discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated di [Read more]